Could Medicare 340B Payment Cuts Lead Hospitals To Buy At List Price?
Executive Summary
Pew Charitable Trusts' Allan Coukell warns the Centers for Medicare and Medicaid Services that its proposal to reduce Medicare Part B drug payments to 340B hospitals may have 'unintended consequences.'
You may also be interested in...
Number One With A Bullet: Eylea Takes Top Spot In Medicare Part B Drugs
Regeneron’s Eylea is the new holder of the number one spot in Medicare Part B prescription drug payments. It is also the fastest growing entrant on the top-ten list tracked by MedPAC. That is a sign of great commercial success – but could be an uncomfortable spotlight.
340B Reforms: Oversight Hearing Suggests Slow, Piecemeal Approach
There appears to be bipartisan interest in beefing up HRSA’s ability to oversee the 340B program – but the next step is likely to be more hearings and fact-finding, not immediate legislative changes.
Closing The Spread: 340B Providers Face Sharp Cuts Under Medicare Proposal
Medicare payments to hospitals for drugs provided under the 340B program would be reduced to average sales price (ASP) minus 22.5%, which CMS believes is more closely aligned with the discounted price obtained by the providers.